Fulminant type I cryoglobulinemic glomerulonephritis with unique ultrastructural plugs: a case report

[1]  Shaji K. Kumar,et al.  The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance , 2021, American journal of hematology.

[2]  S. Rubinstein,et al.  Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom Macroglobulinemia , 2020, Frontiers in Oncology.

[3]  N. Dunbar,et al.  Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue , 2019, Journal of clinical apheresis.

[4]  J. Levy,et al.  Autologous Stem Cell Transplant for the Treatment of Type I Crystal Cryoglobulinemic Glomerulonephritis Caused by Monoclonal Gammopathy of Renal Significance (MGRS) , 2019, Kidney international reports.

[5]  V. D’Agati,et al.  The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group , 2018, Nature Reviews Nephrology.

[6]  C. Selmi,et al.  HCV-negative mixed cryoglobulinemia and kidney involvement: in-depth review on physiopathological and histological bases , 2018, Clinical and Experimental Medicine.

[7]  D. Dingli,et al.  Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia , 2017, American journal of hematology.

[8]  A. Dispenzieri,et al.  Diagnosis of monoclonal gammopathy of renal significance. , 2015, Kidney international.

[9]  D. Lipsker,et al.  Clinico‐biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases , 2015, British journal of haematology.

[10]  S. Maruyama,et al.  A case of acute renal failure of multiple myeloma due to monoclonal type I cryoglobulinemia with thrombotic microangiopathy , 2015, CEN Case Reports.

[11]  B. Grosbois,et al.  Long‐term outcome of monoclonal (type 1) cryoglobulinemia , 2014, American journal of hematology.

[12]  M. Drayson,et al.  How I treat monoclonal gammopathy of renal significance (MGRS). , 2013, Blood.

[13]  Mark E. Williams,et al.  Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue , 2013, Journal of clinical apheresis.

[14]  W. Koldingsnes,et al.  Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review , 2013, International Journal of Hematology.

[15]  J. Tamburini,et al.  Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature , 2013, Leukemia & lymphoma.

[16]  X. Mariette,et al.  The Spectrum of Type I Cryoglobulinemia Vasculitis , 2013, Medicine.

[17]  Y. Kataoka,et al.  Cryoglobulinemia (review). , 2012, Molecular medicine reports.

[18]  Y. Yamaguchi,et al.  Glomerular capillary light chain thrombi in multiple myeloma. , 2011, Kidney international.

[19]  D. Droz,et al.  Renal involvement in monoclonal (type I) cryoglobulinemia: two cases associated with IgG3 kappa cryoglobulin. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  S. Montoto,et al.  Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases , 2001, British journal of haematology.

[21]  H. Kwaan,et al.  The Hyperviscosity Syndromes , 1999, Seminars in thrombosis and hemostasis.

[22]  P. Trautman,et al.  Kinetics of the precipitation of cryoimmunoglobulins. , 1987, Molecular immunology.

[23]  J. Clauvel,et al.  Biologic and clinical significance of cryoglobulins. A report of 86 cases. , 1974, The American journal of medicine.

[24]  R. Williams,et al.  Hyperviscosity Syndromes , 1968, Circulation.